Lowest-Rated Stocks NASDAQ:CTMX CytomX Therapeutics - CTMX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.53 -0.26 (-14.53%) (As of 03/28/2023 11:45 AM ET) Add Compare Share Share Today's Range$1.43▼$1.6150-Day Range$1.69▼$2.8452-Week Range$1.17▼$3.02Volume2.04 million shsAverage Volume2.73 million shsMarket Capitalization$101.10 millionP/E RatioN/ADividend YieldN/APrice Target$3.46 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability CytomX Therapeutics MarketRank™ ForecastAnalyst RatingHold2.09 Rating ScoreUpside/Downside109.3% Upside$3.17 Price TargetShort InterestHealthy2.90% of Float Sold ShortDividend StrengthN/ASustainability-0.74Upright™ Environmental ScoreNews Sentiment-0.01Based on 13 Articles This WeekInsider TradingSelling Shares$30,332 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.31) to ($0.79) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.28 out of 5 starsMedical Sector306th out of 1,002 stocksPharmaceutical Preparations Industry133rd out of 488 stocks 3.0 Analyst's Opinion Consensus RatingCytomX Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.09, and is based on 2 buy ratings, 8 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.17, CytomX Therapeutics has a forecasted upside of 109.3% from its current price of $1.52.Amount of Analyst CoverageCytomX Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.90% of the float of CytomX Therapeutics has been sold short.Short Interest Ratio / Days to CoverCytomX Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CytomX Therapeutics has recently increased by 48.03%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCytomX Therapeutics does not currently pay a dividend.Dividend GrowthCytomX Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCytomX Therapeutics has received a 74.21% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health", "Basic medical research services", and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for CytomX Therapeutics is -0.74. Previous Next 2.2 News and Social Media Coverage News SentimentCytomX Therapeutics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for CytomX Therapeutics this week, compared to 1 article on an average week.Search Interest14 people have searched for CTMX on MarketBeat in the last 30 days. This is an increase of 27% compared to the previous 30 days.MarketBeat Follows2 people have added CytomX Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CytomX Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,332.00 in company stock.Percentage Held by InsidersOnly 6.50% of the stock of CytomX Therapeutics is held by insiders.Percentage Held by Institutions70.14% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CytomX Therapeutics are expected to grow in the coming year, from ($1.31) to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CytomX Therapeutics is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CytomX Therapeutics is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytomX Therapeutics has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About CytomX Therapeutics (NASDAQ:CTMX) StockCytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.Read More Receive CTMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CTMX Stock News HeadlinesMarch 27, 2023 | finance.yahoo.comCytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business UpdateMarch 26, 2023 | americanbankingnews.comStockNews.com Downgrades CytomX Therapeutics (NASDAQ:CTMX) to SellMarch 28, 2023 | Press Research (Ad)Nevada Could be the Source for America's Green FutureIndustry shift towards lithium driven by green energy goalsMarch 24, 2023 | msn.comCytomX Therapeutics Earnings PreviewMarch 23, 2023 | americanbankingnews.comAnalysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Target Price at $3.46March 22, 2023 | finance.yahoo.comCytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023March 22, 2023 | americanbankingnews.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) CEO Sean A. Mccarthy Sells 7,121 SharesMarch 20, 2023 | finance.yahoo.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) is definitely on the radar of institutional investors who own 42% of the companyMarch 28, 2023 | Press Research (Ad)Nevada Could be the Source for America's Green FutureIndustry shift towards lithium driven by green energy goalsMarch 20, 2023 | americanbankingnews.comCytomX Therapeutics (NASDAQ:CTMX) Earns Hold Rating from Analysts at StockNews.comMarch 1, 2023 | finance.yahoo.comCytomX Therapeutics to Present at Upcoming March Investor ConferencesJanuary 26, 2023 | finanznachrichten.deCytomX Therapeutics Inc.: CytomX Therapeutics Announces Milestone Achievement in Probody T-Cell Engaging Bispecific (TCB) Collaboration with AstellasJanuary 26, 2023 | finance.yahoo.comCytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with AstellasJanuary 26, 2023 | finance.yahoo.comCytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with AstellasJanuary 22, 2023 | seekingalpha.comCytomX Therapeutics (CTMX) Presents at the 41st Annual J.P. Morgan Healthcare Conference - SlideshowJanuary 17, 2023 | finance.yahoo.comCytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor ConferenceJanuary 12, 2023 | finance.yahoo.comAn Intrinsic Calculation For CytomX Therapeutics, Inc. (NASDAQ:CTMX) Suggests It's 38% UndervaluedJanuary 7, 2023 | finanznachrichten.deCytomX Therapeutics Inc.: CytomX Therapeutics Provides Business Update and Outlines 2023 Company PrioritiesJanuary 7, 2023 | finanznachrichten.deCytomX Therapeutics Inc.: CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated TherapeuticsJanuary 7, 2023 | seekingalpha.comCytomX shares soar +50% on collaboration with Moderna to make mRNA-based therapies (update)December 22, 2022 | tmcnet.comCytomX Therapeutics to Outline 2023 Company Priorities andDecember 22, 2022 | finance.yahoo.comCytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023December 22, 2022 | finance.yahoo.comWe're A Little Worried About CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn RateDecember 20, 2022 | finance.yahoo.comCytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 7, 2022 | tmcnet.comCytomX Therapeutics to Present Phase 2 Data forDecember 7, 2022 | finance.yahoo.comCytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer SymposiumNovember 18, 2022 | theglobeandmail.comCytomX Therapeutics (NASDAQ: CTMX) and Regeneron (NASDAQ: REGN) Enter into Strategic Collaboration to Develop Bispecific Therapies to Treat CancerSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CTMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CTMX Company Calendar Last Earnings11/04/2021Today3/27/2023Next Earnings (Confirmed)3/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CTMX CUSIPN/A CIK1501989 Webwww.cytomx.com Phone(605) 515-3185Fax650-351-0353Employees174Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.46 High Stock Price Forecast$8.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+93.1%Consensus RatingHold Rating Score (0-4)2.09 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($1.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,610,000.00 Net Margins-135.65% Pretax Margin-135.65% Return on Equity-166.29% Return on Assets-34.77% Debt Debt-to-Equity RatioN/A Current Ratio2.05 Quick Ratio2.05 Sales & Book Value Annual Sales$69.57 million Price / Sales1.70 Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book1.31Miscellaneous Outstanding Shares66,080,000Free Float61,789,000Market Cap$118.28 million OptionableOptionable Beta0.69 Key ExecutivesSean A. McCarthyChairman, President & Chief Executive OfficerChris OgdenChief Financial & Accounting OfficerMarcia P. BelvinSenior Vice President & Head-ResearchLloyd A. RowlandSecretary, Chief Compliance Officer & Senior VPDanielle OlanderSenior VP-Talent & Systems DevelopmentKey CompetitorsVeruNASDAQ:VERUDURECTNASDAQ:DRRXEsperion TherapeuticsNASDAQ:ESPRMilestone PharmaceuticalsNASDAQ:MISTGalectin TherapeuticsNASDAQ:GALTView All CompetitorsInsiders & InstitutionsSean A MccarthySold 7,121 sharesTotal: $13,387.48 ($1.88/share)Lloyd A RowlandSold 2,037 sharesTotal: $4,033.26 ($1.98/share)Amy C PetersonSold 4,257 sharesTotal: $8,428.86 ($1.98/share)Carlos CampoySold 1,748 sharesTotal: $3,461.04 ($1.98/share)Christopher OgdenSold 516 sharesTotal: $1,021.68 ($1.98/share)View All Insider TransactionsView All Institutional Transactions CTMX Stock - Frequently Asked Questions Should I buy or sell CytomX Therapeutics stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 1 sell rating, 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CTMX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTMX, but not buy additional shares or sell existing shares. View CTMX analyst ratings or view top-rated stocks. What is CytomX Therapeutics' stock price forecast for 2023? 11 brokerages have issued 1 year target prices for CytomX Therapeutics' shares. Their CTMX share price forecasts range from $1.50 to $8.00. On average, they anticipate the company's stock price to reach $3.17 in the next year. This suggests a possible upside of 109.3% from the stock's current price. View analysts price targets for CTMX or view top-rated stocks among Wall Street analysts. How have CTMX shares performed in 2023? CytomX Therapeutics' stock was trading at $1.60 at the beginning of the year. Since then, CTMX shares have decreased by 5.3% and is now trading at $1.5150. View the best growth stocks for 2023 here. Are investors shorting CytomX Therapeutics? CytomX Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 1,880,000 shares, an increase of 48.0% from the February 28th total of 1,270,000 shares. Based on an average daily trading volume, of 2,490,000 shares, the days-to-cover ratio is currently 0.8 days. Currently, 2.9% of the shares of the company are short sold. View CytomX Therapeutics' Short Interest. When is CytomX Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our CTMX earnings forecast. How were CytomX Therapeutics' earnings last quarter? CytomX Therapeutics, Inc. (NASDAQ:CTMX) announced its earnings results on Thursday, November, 4th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.05. The biotechnology company earned $17.59 million during the quarter, compared to the consensus estimate of $18.53 million. CytomX Therapeutics had a negative net margin of 135.65% and a negative trailing twelve-month return on equity of 166.29%. During the same period last year, the business posted ($0.32) EPS. What ETFs hold CytomX Therapeutics' stock? ETFs with the largest weight of CytomX Therapeutics (NASDAQ:CTMX) stock in their portfolio include Formidable ETF (FORH).Invesco Nasdaq Future Gen 200 ETF (QQQS). What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO? 12 employees have rated CytomX Therapeutics Chief Executive Officer Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among the company's employees. 80.0% of employees surveyed would recommend working at CytomX Therapeutics to a friend. What other stocks do shareholders of CytomX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX). What is CytomX Therapeutics' stock symbol? CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX." Who are CytomX Therapeutics' major shareholders? CytomX Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Tang Capital Management LLC (5.31%), Millennium Management LLC (2.60%), Renaissance Technologies LLC (2.03%), Assenagon Asset Management S.A. (1.38%), Two Sigma Investments LP (1.12%) and Platinum Investment Management Ltd. (0.96%). Insiders that own company stock include Amy C Peterson, Carlos Campoy, Christopher Ogden, Jeffrey B Landau, Lloyd A Rowland and Sean A Mccarthy. View institutional ownership trends. How do I buy shares of CytomX Therapeutics? Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CytomX Therapeutics' stock price today? One share of CTMX stock can currently be purchased for approximately $1.52. How much money does CytomX Therapeutics make? CytomX Therapeutics (NASDAQ:CTMX) has a market capitalization of $100.11 million and generates $69.57 million in revenue each year. The biotechnology company earns $-83,610,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. How many employees does CytomX Therapeutics have? The company employs 174 workers across the globe. How can I contact CytomX Therapeutics? CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytomx.com. The biotechnology company can be reached via phone at (605) 515-3185, via email at ckeenan@cytomx.com, or via fax at 650-351-0353. This page (NASDAQ:CTMX) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.